Nortis Awarded USD 688K NIH Phase II SBIR Fast Track Grant to Develop Living Model of Human Blood-Brain Barrier
SEATTLE, Aug. 18, 2017 : Nortis today announced the awarding of a USD 688K National Institutes of Health (NIH) grant. The award will provide funding for the third year of a Small Business Innovation Research (SBIR) Fast-track grant under award number R44NS095585 from the National Institute of Neurological Disorders and Stroke (NINDS). 
The neurotherapeutics sector is among the largest and fastest growing markets in the pharmaceutical industry. Progress has been slow due to the lack of in-vitro assays that reliably predict outcomes in humans. The grant will allow Nortis to expand applications for its proprietary ParVivo system into the field of human blood-brain barrier (BBB), addressing the critically unmet need for more effective in-vitro testing systems that model human brain diseases such as Alzheimer's, multiple sclerosis, Parkinson's, stroke and cancer.

"Understanding how drugs are transported across the blood-brain barrier and interact with the brain presents a significant scientific challenge," said Dr. Thomas Neumann, CEO of Nortis and Principal Investigator on this project. "More predictive preclinical models based on human tissue are urgently needed to reduce costs and minimize clinical trial failures. This grant will help us develop new in-vitro alternatives to traditional pharmaceutical drug development testing on laboratory animals."
https://www.newkerala.com/us-news.php

(Posted on 18 August 2017, 1675571884 3O236O47O240)